155 related articles for article (PubMed ID: 15290732)
1. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
Stern R; Wolfe F
J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
[TBL] [Abstract][Full Text] [Related]
2. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
[TBL] [Abstract][Full Text] [Related]
3. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
5. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
6. Dose intensification with infliximab in patients with rheumatoid arthritis.
Berger A; Edelsberg J; Li TT; Maclean JR; Oster G
Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073
[TBL] [Abstract][Full Text] [Related]
7. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
Harley CR; Frytak JR; Tandon N
Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
[TBL] [Abstract][Full Text] [Related]
8. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
9. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
10. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
11. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
Haraoui B; Cameron L; Ouellet M; White B
J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy in established rheumatoid arthritis: an observational study.
Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
[TBL] [Abstract][Full Text] [Related]
13. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Haraoui B; Keystone EC; Thorne JC; Pope JE; Chen I; Asare CG; Leff JA
J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
[TBL] [Abstract][Full Text] [Related]
15. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center.
Agarwal SK; Maier AL; Chibnik LB; Coblyn JS; Fossel A; Lee R; Fanikos J; Fiumara K; Lowry C; Weinblatt ME
Arthritis Rheum; 2005 Dec; 53(6):872-8. PubMed ID: 16342095
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
[TBL] [Abstract][Full Text] [Related]
17. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.
van Vollenhoven RF; Klareskog L
Scand J Rheumatol; 2007; 36(6):418-23. PubMed ID: 18092261
[TBL] [Abstract][Full Text] [Related]
18. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
20. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
